| Biological Information | |
|---|---|
| Background Information: | VX-809 (Lumacaftor) is an experimental drug for the treatment of cystic fibrosis in development by Vertex Pharmaceuticals. VX-809 is designed to be effective in patients that have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease. F508del, meaning that the amino acid phenylalanine in position 508 is missing, is found in about 60% of cystic fibrosis patients in Europe, and in about 90% of persons with some mutation in the CFTR gene. |
| Target Name: | Lumacaftor |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at -20°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
VX-809 (Lumacaftor)
VX-809 (Lumacaftor) is termed a cystic fibrosis transmembrane conductance regulator (CFTR) corrector, acting to reduce mis-folding of the defective F508del mutant CFTR protein, in comparison to Ivacaftor which is termed a CFTR potentiator drug.
Datasheets
92-1248 Datasheet
View Document